Novozymes A/S - NVZMY Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novozymes A/S in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Novozymes A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVZMY, but not buy additional shares or sell existing shares.
View analyst ratings for Novozymes A/S or view top-rated stocks.

8 Wall Street analysts have issued 12-month price targets for Novozymes A/S's stock. Their NVZMY stock forecasts range from $360.00 to $490.00. On average, they anticipate Novozymes A/S's share price to reach $425.00 in the next twelve months. This suggests a possible upside of 619.7% from the stock's current price.
View analysts' price targets for Novozymes A/S or view top-rated stocks among Wall Street analysts.

Novozymes A/S's stock was trading at $83.12 on January 1st, 2022. Since then, NVZMY stock has decreased by 29.0% and is now trading at $59.05.
View the best growth stocks for 2022 here.

Novozymes A/S saw a increase in short interest in July. As of July 15th, there was short interest totaling 9,100 shares, an increase of 550.0% from the June 30th total of 1,400 shares. Based on an average trading volume of 41,200 shares, the days-to-cover ratio is currently 0.2 days.
View Novozymes A/S's Short Interest.

Novozymes A/S (OTCMKTS:NVZMY) released its quarterly earnings results on Wednesday, April, 29th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.42. The biotechnology company had revenue of $558.75 million for the quarter. Novozymes A/S had a net margin of 19.92% and a trailing twelve-month return on equity of 26.71%.

Novozymes A/S announced a dividend on Tuesday, March 15th. Shareholders of record on Friday, March 18th will be given a dividend of $0.567 per share on Tuesday, April 5th. This represents a yield of 0.95%. The ex-dividend date of this dividend is Thursday, March 17th.
View Novozymes A/S's dividend history.

Novozymes A/S(OTCMKTS:NVZMY) pays an annual dividend of $0.55 per share and currently has a dividend yield of 0.92%. The dividend payout ratio of Novozymes A/S is 30.39%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novozymes A/S will have a dividend payout ratio of 30.22% next year. This indicates that Novozymes A/S will be able to sustain or increase its dividend.
View Novozymes A/S's dividend history.

Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMY."

Shares of NVZMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVZMY stock can currently be purchased for approximately $59.05.

Novozymes A/S (OTCMKTS:NVZMY) has a market capitalization of $13.42 billion and generates $2.38 billion in revenue each year. The biotechnology company earns $500.53 million in net income (profit) each year or $1.81 on an earnings per share basis.

Novozymes A/S employs 6,527 workers across the globe.

Novozymes A/S was founded in 2000.

Novozymes A/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The official website for Novozymes A/S is www.novozymes.com. The biotechnology company can be reached via phone at (454) 446-0000, via email at novozymesir@novozymes.com, or via fax at 45-4446-9999.